PharmAbs is a KU Leuven innovation, valorisation and incubation platform for the development of antibody-based therapeutics and diagnostics. PharmAbs’ expertise and technologies are used to translate basic scientific innovations emerging at universities into diagnostic/therapeutic solutions for personalized medicine that can be implemented in the clinic and/or commercialized by third parties.
PharmAbs offers antibody solutions to academic groups and companies. Read more.
Technology offers and licensing opportunities. Read more
PharmAbs established a structural collaboration with KU Leuven MeBios to develop integrated diagnostics and life science research tools.
Program Complete |IBRD 2019| 4-5 November 2019 | Leuven
Join us to get the latest updates on breaking innovations in rare diseases and orphan drugs from frontline speakers.
Who should attend? Junior & senior researchers, clinicians, pharma, policy makers, patient organisations active in the field of rare diseases or orphan drugs.
To register, please click here. Early bird registration until 1 September 2019.
Further questions? Please contact firstname.lastname@example.org
PharmAbs in the press: